

Technical Data Sheet



Bispecific anti-mouse PD-L1 x anti-mouse CTLA-4

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at <https://bioxcell.com/terms-and-conditions>.

Lot Specific Information

Lot Number: Lot Specific*
Volume: Lot Specific*
Concentration: Lot Specific* (generally 4 to 11 mg/ml) *
Total Protein: Lot Specific*

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number: CPB512
Clone: Derived from clones 10F.9G2 and 9D9
Isotype: Mouse IgG2a-scFv, κ
Recommended Dilution Buffer: InVivoPure pH 7.0 Dilution Buffer
Reported Applications: ELISA
For information on in-vivo applications, please contact technicalservice@bioxcell.com
Formulation: PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin: ≤ 0.5 EU/mg (≤ 0.0005 EU/ μ g)
Determined by LAL assay
Purity: $\geq 95\%$
Determined by SDS-PAGE
Sterility: 0.2 μ m filtration
Production: Purified from mammalian cell supernatant in an animal-free facility
Purification: Protein G
RRID:
Molecular Weight: 200.9 kDa

Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

Description

CPB512 is a 2+2 symmetric tetravalent bispecific engineered to simultaneously target mouse programmed death-ligand 1 (PD-L1, CD274, B7-H1) and mouse cytotoxic T-lymphocyte associated protein 4 (CTLA-4, CD152) proteins. CPB512 contains the murine IgG2a constant region to regulate effector function such as Fc receptor binding and complement activation—and reduce immunogenicity and the formation of anti-drug antibodies (ADAs) in mouse models. This bispecific was designed to block two major immune checkpoint molecules involved in suppressing the immune response against tumors. Anti-PD-L1 x anti-CTLA-4 bispecific antibodies enhance anticancer immunity by synergistically boosting T cell activation and relieving checkpoint-mediated immunosuppression in both lymphoid tissues and the tumor microenvironment.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**

It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at

<https://bioxcell.com/faqs>.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit https://bioxcell.com/cpb512?bxcs=9k1b3a#tab_references or scan the QR code below.



Bio X Cell, LLC

<https://bioxcell.com>

+1-866-787-3444

customerservice@bioxcell.com

Conditions: For research use only. Not for use in diagnostic or therapeutic procedures.

Not for resale.

Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2026 Bio X Cell, LLC